Jeong Yisun, Kim Hyungjoo, You Daeun, Cho Soo Youn, Yoon Sun Young, Kim Seok Won, Nam Seok Jin, Lee Jeong Eon, Kim Sangmin
Department of Breast Cancer Center, Samsung Medical Center, 81 Irwon-Ro, Gangnam-gu, Seoul 06351, Republic of Korea.
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-gu, Seoul 06351, Republic of Korea.
Cells. 2024 Dec 28;14(1):19. doi: 10.3390/cells14010019.
Sushi domain-containing protein 2 (SUSD2), a transmembrane protein containing a sushi motif, has been reported to have tumor-promoting functions in various types of cancer, including breast cancer. However, the regulatory mechanism of SUSD2 and its function in HER2-positive (HER2+) breast cancer have not been fully identified as yet. In this study, we explored the potential of targeting SUSD2 to overcome trastuzumab (TRZ) resistance in HER2+ breast cancer. SUSD2 expression was found to be significantly increased in HER2-overexpressing cells. Endogenous SUSD2 expression was observed in HER2+ breast cancer cells but not in estrogen receptor-positive or triple-negative breast cancer cells. We also found that SUSD2 expression was positively correlated with HER2 expression in a publicly available human primary breast cancer dataset. Although SUSD2 expression was associated with HER2, its expression levels were not affected by TRZ. Through kinase array experiments, we found that SUSD2 expression was modulated downstream of STAT3-dependent signaling in breast cancer cells overexpressing HER2. STAT3 activity was increased in EGFR+ HER2+ breast cancer cells compared to EGFR+ cells. Furthermore, we observed that SUSD2 expression was decreased by C188-9, a STAT3-specific inhibitor. Finally, we analyzed the association between patient survival and SUSD2 expression in breast cancer. Our results showed that SUSD2 expression had a negative correlation with the relapse-free survival of patients with EGFR+ HER2+ breast cancer when compared to EGFR+ breast cancer patients. Collectively, our results demonstrate that SUSD2 expression is mediated by STAT3 and imply the potential of using SUSD2 as a biomarker to stratify HER2+ breast cancer.
含寿司结构域蛋白2(SUSD2)是一种含有寿司模体的跨膜蛋白,据报道在包括乳腺癌在内的多种癌症中具有促肿瘤功能。然而,SUSD2的调控机制及其在人表皮生长因子受体2阳性(HER2+)乳腺癌中的作用尚未完全明确。在本研究中,我们探讨了靶向SUSD2以克服HER2+乳腺癌中曲妥珠单抗(TRZ)耐药的潜力。我们发现SUSD2在HER2过表达细胞中显著上调。HER2+乳腺癌细胞中可观察到内源性SUSD2表达,而雌激素受体阳性或三阴性乳腺癌细胞中未观察到。我们还发现,在公开的人类原发性乳腺癌数据集中,SUSD2表达与HER2表达呈正相关。虽然SUSD2表达与HER2相关,但其表达水平不受TRZ影响。通过激酶阵列实验,我们发现SUSD2表达在过表达HER2的乳腺癌细胞中受STAT3依赖性信号通路的下游调控。与EGFR+细胞相比,EGFR+HER2+乳腺癌细胞中STAT3活性增加。此外,我们观察到STAT3特异性抑制剂C188-9可降低SUSD2表达。最后,我们分析了乳腺癌患者生存与SUSD2表达之间的关系。我们的结果表明,与EGFR+乳腺癌患者相比,EGFR+HER2+乳腺癌患者中SUSD2表达与无复发生存呈负相关。总体而言,我们的结果表明SUSD2表达由STAT3介导,并暗示SUSD2作为HER2+乳腺癌分层生物标志物的潜力。